[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.238.248.103. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 517
Citations 0
Research Letter
July 1, 2020

Use of Adjuvant Radiotherapy in the Treatment of High-risk Cutaneous Squamous Cell Carcinoma With Perineural Invasion

Author Affiliations
  • 1The Ronald O. Perelman Department of Dermatology, New York University School of Medicine, New York
  • 2The Skin Surgery Center, Bain Dermatology, Raleigh, North Carolina
  • 3Northwell Health, New Hyde Park, New York
JAMA Dermatol. Published online July 1, 2020. doi:10.1001/jamadermatol.2020.1984

Perineural invasion in cutaneous squamous cell carcinoma (cSCC) is associated with an increased risk of local recurrence, nodal metastases, and disease-specific death. Adjuvant radiotherapy has been suggested to mitigate aggressive behavior of cSCC with perineural invasion.1-3 To clarify the utility of adjuvant radiotherapy for cSCC with perineural invasion, we investigated the outcomes of local recurrence, nodal metastases, distant metastases, and disease-free survival of patients treated surgically with or without adjuvant radiotherapy.

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    ×